{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LAM&page=6", "query": { "condition": "LAM", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 249, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LAM&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LAM&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T20:17:01.448Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02120352", "title": "A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "CAB Oral Tablets", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" }, { "name": "ABC/3TC Oral tablets", "type": "DRUG" }, { "name": "RPV Oral Tablets", "type": "DRUG" }, { "name": "HAART", "type": "OTHER" }, { "name": "RPV", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2014-04-28", "completion_date": "2023-04-20", "has_results": true, "last_update_posted_date": "2024-06-12", "last_synced_at": "2026-10-27T20:17:01.448Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02120352" }, { "nct_id": "NCT00128193", "title": "Leprosy Skin Test Antigens Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leprosy" ], "interventions": [ { "name": "Tuberculin, Purified Protein Derivative", "type": "BIOLOGICAL" }, { "name": "MLSA-LAM", "type": "OTHER" }, { "name": "MLCwA", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 260, "start_date": "2002-04", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2014-12-24", "last_synced_at": "2026-10-27T20:17:01.448Z", "location_count": 1, "location_summary": "Fort Collins, Colorado", "locations": [ { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00128193" }, { "nct_id": "NCT04021290", "title": "Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DTG/3TC FDC", "type": "DRUG" }, { "name": "CAR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 493, "start_date": "2019-11-11", "completion_date": "2022-09-09", "has_results": true, "last_update_posted_date": "2023-10-19", "last_synced_at": "2026-10-27T20:17:01.448Z", "location_count": 16, "location_summary": "Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04021290" }, { "nct_id": "NCT01059318", "title": "A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphangioleiomyomatosis" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2010-01", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2020-11-19", "last_synced_at": "2026-10-27T20:17:01.448Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Cincinnati, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01059318" }, { "nct_id": "NCT00737568", "title": "Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis B" ], "interventions": [ { "name": "TDF", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "TDF Placebo", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 280, "start_date": "2008-09", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-03-11", "last_synced_at": "2026-10-27T20:17:01.448Z", "location_count": 3, "location_summary": "Bradenton, Florida • Flushing, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Bradenton", "state": "Florida" }, { "city": "Flushing", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00737568" }, { "nct_id": "NCT02432560", "title": "Safety and Durability of Sirolimus for Treatment of LAM", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphangioleiomyomatosis" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 600, "start_date": "2015-03", "completion_date": "2025-07-31", "has_results": false, "last_update_posted_date": "2024-12-24", "last_synced_at": "2026-10-27T20:17:01.448Z", "location_count": 20, "location_summary": "Stanford, California • Denver, Colorado • Jacksonville, Florida + 17 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02432560" }, { "nct_id": "NCT02603120", "title": "Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "ABC/DTG/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "ABC/DTG/3TC Placebo", "type": "DRUG" }, { "name": "B/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 567, "start_date": "2015-11-11", "completion_date": "2019-10-23", "has_results": true, "last_update_posted_date": "2020-11-12", "last_synced_at": "2026-10-27T20:17:01.448Z", "location_count": 61, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 48 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603120" }, { "nct_id": "NCT00104429", "title": "GW873140 In Combination With Combivir In HIV Infected Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus I", "HIV Infection" ], "interventions": [ { "name": "GW873140", "type": "DRUG" }, { "name": "Combivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2005-01", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-27T20:17:01.448Z", "location_count": 27, "location_summary": "Bakersfield, California • Beverly Hills, California • Los Angeles, California + 21 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104429" }, { "nct_id": "NCT04696575", "title": "Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Lung Small Cell Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2021-07-02", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-10-27T20:17:01.448Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04696575" }, { "nct_id": "NCT00076336", "title": "Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis", "Hepatitis B, Chronic", "Cirrhosis" ], "interventions": [ { "name": "Telbivudine", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 232, "start_date": "2003-12", "completion_date": null, "has_results": true, "last_update_posted_date": "2011-09-05", "last_synced_at": "2026-10-27T20:17:01.448Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00076336" } ] }